Clinical Trials · NCT05891093
Efficacy and Safety of Fluzoparib Combined With Adjuvant Endocrine Therapy for HR+/HER2- SNF3-subtype Early Breast Cancer (BCTOP-L-A01)
- Phase
- Phase 3
- Recruitment status
- Recruiting
- Sponsor
- Fudan University
- Enrollment
- 766
- Start date
- Jun 2023
- Locations
- 15 sites, China
- Primary endpoint
- invasive disease free survival (iDFS)